Atrium Therapeutics (RNA)
Targets genetic drivers of rare cardiomyopathies with tissue-directed siRNA medicines.
$8.43
vs last close−0.79 (−8.60%)
In millions of USD, except per-share figures
| In millions | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|
| Revenue | 0 | 1 | 20 | 3 |
| Cost of revenue | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 1 | 19 | 3 |
| 8 | 49 | 37 | 25 | |
| Research & development | 0 | 18 | 17 | 15 |
| 0 | 30 | 20 | 10 | |
| Selling & marketing | −6 | 0 | 0 | 0 |
| General & administrative | 6 | 30 | 0 | 0 |
| Other expenses | 8 | 0 | 0 | 0 |
| Operating income | −8 | −48 | −17 | −23 |
| 0 | 0 | 1 | 2 | |
| Interest income | 0 | 0 | 0 | 2 |
| Other non-operating income | 0 | 0 | −1 | 0 |
| Income before tax | −8 | −48 | −17 | −20 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −8 | −48 | −17 | −20 |
| Net income | −8 | −48 | −17 | −20 |
| EPS, basic | $0.00 | −$1.70 | −$0.97 | −$1.18 |
| EPS, diluted | $0.00 | −$1.70 | −$0.97 | −$1.18 |
| Weighted average shares, basic | 0 | 17 | 17 | 17 |
| Weighted average shares, diluted | 0 | 17 | 17 | 17 |
| EBITDA | −8 | −48 | −16 | −22 |
| Depreciation & amortization | 0 | 0 | 0 | 0 |
| EBIT | −8 | −48 | −17 | −23 |